Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma
…, R Tabrizi, E Hermet, J Lazarovici… - Blood, The Journal …, 2017 - ashpublications.org
Allogeneic hematopoietic cell transplantation (allo-HCT) is indicated for patients with
relapsed or refractory Hodgkin lymphoma (HL). Although long-term disease control can be …
relapsed or refractory Hodgkin lymphoma (HL). Although long-term disease control can be …
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study
…, T Comont, N Kramkimel, J Lazarovici… - The Lancet …, 2019 - thelancet.com
Background Anti-programmed cell death 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1)
antibodies are novel immunotherapies for cancer that can induce immune-related …
antibodies are novel immunotherapies for cancer that can induce immune-related …
[PDF][PDF] Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus …
…, F Morschhauser, C Haioun, J Lazarovici… - Journal of Clinical …, 2017 - researchgate.net
Purpose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is
rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-…
rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-…
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study
…, R Bouabdallah, P Brice, J Lazarovici… - The lancet …, 2019 - thelancet.com
Background Increased-dose bleomycin, etoposide, doxorubicin, cyclophosphamide,
vincristine, procarbazine, and prednisone (BEACOPP escalated ) improves progression-free …
vincristine, procarbazine, and prednisone (BEACOPP escalated ) improves progression-free …
18F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti–programmed death 1 …
The response evaluation criteria in patients with Hodgkin lymphoma (HL) were designed for
the assessment of chemotherapy and targeted molecular agents. We investigated the …
the assessment of chemotherapy and targeted molecular agents. We investigated the …
Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non …
…, F Jardin, JN Bastie, S Amorim, J Lazarovici… - The Lancet …, 2015 - thelancet.com
Background Romidepsin is a histone deacetylase inhibitor approved in the USA for patients
with recurrent or refractory peripheral T-cell lymphoma and has shown activity in this setting …
with recurrent or refractory peripheral T-cell lymphoma and has shown activity in this setting …
Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: a series from lysa centers
…, L Ysebaert, L Obéric, J Lazarovici… - American journal of …, 2018 - Wiley Online Library
Anti‐PD‐1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who
have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and …
have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and …
[HTML][HTML] EZH2 alterations in follicular lymphoma: biological and clinical correlations
…, E Sohier, M Carrère, J Lazarovici… - Blood cancer …, 2017 - nature.com
The histone methyltransferase EZH2 has an essential role in the development of follicular
lymphoma (FL). Recurrent gain-of-function mutations in EZH2 have been described in 25% of …
lymphoma (FL). Recurrent gain-of-function mutations in EZH2 have been described in 25% of …
Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial
LM Fornecker, J Lazarovici, I Aurer… - Journal of clinical …, 2023 - ingentaconnect.com
PURPOSE The prognosis of patients with early-stage unfavorable Hodgkin lymphoma
remains unsatisfactory. We assessed the efficacy and safety of brentuximab vedotin plus …
remains unsatisfactory. We assessed the efficacy and safety of brentuximab vedotin plus …
Expression of the immune checkpoint regulators LAG-3 and TIM-3 in classical Hodgkin lymphoma
…, P Gravelle, V Marty, A Danu, J Lazarovici… - … Myeloma and Leukemia, 2021 - Elsevier
Introduction The role of the programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1)
axis is well established in classical Hodgkin lymphoma (HL), where PD-1 blockade …
axis is well established in classical Hodgkin lymphoma (HL), where PD-1 blockade …